A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Anemia in Myelodysplastic Syndromes Clinical Trial

Official title:
A Phase 1/2, Open-Label Clinical Study To Evaluate Safety And Efficacy Of TP-0184 To Treat Anemia When Administered To Adult Patients With IPSS-R Low Or Intermediate Risk Myelodysplastic Syndromes

Status Terminated

Clinical Trial Summary

This study will evaluate preliminary safety and efficacy of TP-0184 to treat anemia when administered to adult patients with Revised International Prognostic Scoring System (IPSS-R) low or intermediate risk MDS. The recommended Phase 2 dose (RP2D) will be determined by the maximum tolerated dose (MTD) or maximum administered dose (MAD) in the Phase 1 portion of the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Anemia
Anemia in Myelodysplastic Syndromes
Myelodysplastic Syndromes
Preleukemia
Syndrome

Clinical Trial Details

NCT number	NCT04623996
Study type	Interventional
Source	Sumitomo Pharma America, Inc.
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	December 28, 2020
Completion date	April 27, 2021

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT00437450` - Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid	Phase 2